Incyte (INCY) Accumulated Expenses (2010 - 2026)
Incyte (INCY) posted Accumulated Expenses of $124.9 million for Q1 2026, down 87.89% on a QoQ basis from $1.0 billion in Q4 2025, and up 21.49% year-over-year from $102.8 million in Q1 2025.
Incyte (INCY) Accumulated Expenses (2010 - 2026) Analysis & Trends
Incyte's Accumulated Expenses history runs 17 years deep, the most recent figure standing at $124.9 million for Q1 2026.
- Quarterly Accumulated Expenses rose 21.49% year-over-year to $124.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.9 million (up 21.49% YoY) and the FY2025 annual result came in at $1.0 billion, up 446.7% from the prior year.
- Accumulated Expenses was $124.9 million for Q1 2026 at Incyte, down from $1.0 billion in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.1 billion in Q1 2024 and bottomed at $9.0 million in Q2 2022.
- A 5-year average of $441.4 million and a median of $168.2 million in 2025 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 5136.59% — and 2025, when it sank 90.67%.
- Incyte's Accumulated Expenses stood at $701.1 million in 2022, then plunged by 78.13% to $153.3 million in 2023, then grew by 23.04% to $188.7 million in 2024, then soared by 446.7% to $1.0 billion in 2025, then sank by 87.89% to $124.9 million in 2026.
- Business Quant data shows INCY's Accumulated Expenses at $124.9 million in Q1 2026, $1.0 billion in Q4 2025, and $168.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Incyte | 23.47 Bn | 19.46 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 124.92 Mn |
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | 168.25 Mn |
| Jun 30, 2025 | 857.09 Mn |
| Mar 31, 2025 | 102.82 Mn |
| Dec 31, 2024 | 188.68 Mn |
| Sep 30, 2024 | 150.72 Mn |
| Jun 30, 2024 | 1.03 Bn |
| Mar 31, 2024 | 1.10 Bn |
| Dec 31, 2023 | 153.35 Mn |
| Sep 30, 2023 | 820.61 Mn |
| Jun 30, 2023 | 111.71 Mn |
| Mar 31, 2023 | 825.44 Mn |
| Dec 31, 2022 | 701.05 Mn |
| Sep 30, 2022 | 106.31 Mn |
| Jun 30, 2022 | 8.95 Mn |
| Mar 31, 2022 | 15.76 Mn |
| Dec 31, 2021 | 108.96 Mn |
| Sep 30, 2021 | 23.89 Mn |
| Jun 30, 2021 | 82.76 Mn |